Bank of America
KYMR icon

Bank of America’s Kymera Therapeutics KYMR Stock Holding History

Bank of America’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$24.1M Sell
289,416
-49,583
-15% -$3.93M ﹤0.01% 2225
2025
Q4 		$26.4M Buy
338,999
+152,745
+82% +$10.3M ﹤0.01% 2059
2025
Q3 		$10.5M Buy
186,254
+51,315
+38% +$2.31M ﹤0.01% 3248
2025
Q2 		$5.89M Buy
134,939
+38,134
+39% +$1.31M ﹤0.01% 3726
2025
Q1 		$2.65M Buy
96,805
+34,545
+55% +$1.26M ﹤0.01% 4424
2024
Q4 		$2.5M Sell
62,260
-48,772
-44% -$2.2M ﹤0.01% 4248
2024
Q3 		$5.26M Sell
111,032
-40,159
-27% -$1.77M ﹤0.01% 3695
2024
Q2 		$4.51M Sell
151,191
-11,100
-7% -$384K ﹤0.01% 3706
2024
Q1 		$6.52M Buy
162,291
+132,293
+441% +$4.73M ﹤0.01% 3382
2023
Q4 		$764K Sell
29,998
-58,667
-66% -$1.05M ﹤0.01% 5186
2023
Q3 		$1.23M Sell
88,665
-51,359
-37% -$1.03M ﹤0.01% 4665
2023
Q2 		$3.22M Sell
140,024
-136,764
-49% -$3.92M ﹤0.01% 3796
2023
Q1 		$8.2M Buy
276,788
+69,905
+34% +$2.25M ﹤0.01% 3028
2022
Q4 		$5.16M Buy
206,883
+81,307
+65% +$2.17M ﹤0.01% 3357
2022
Q3 		$2.73M Buy
125,576
+6,463
+5% +$170K ﹤0.01% 4003
2022
Q2 		$2.35M Sell
119,113
-10,125
-8% -$236K ﹤0.01% 4163
2022
Q1 		$5.47M Buy
129,238
+56,818
+78% +$2.4M ﹤0.01% 3522
2021
Q4 		$4.6M Buy
72,420
+36,414
+101% +$2.12M ﹤0.01% 3742
2021
Q3 		$2.12M Buy
36,006
+27,654
+331% +$1.6M ﹤0.01% 4385
2021
Q2 		$405K Sell
8,352
-24,003
-74% -$1.04M ﹤0.01% 5583
2021
Q1 		$1.26M Buy
32,355
+28,551
+751% +$1.72M ﹤0.01% 4642
2020
Q4 		$236K Buy
3,804
+1,357
+55% +$66.2K ﹤0.01% 5494
2020
Q3 		$79K Buy
+2,447
New +$74.7K ﹤0.01% 5799

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Bank of America's KYMR Position: Q1 2026 in Review

Bank of America reduced its Kymera Therapeutics (KYMR) stake by 15% in Q1 2026, selling an estimated $3.93M and leaving 289,416 shares worth $24.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2225.

Bank of America first reported a position in KYMR in Q3 2020 and has held it in 23 quarters since. The position peaked at $26.4M in Q4 2025. 256 funds tracked by Wall St. Rank hold KYMR as of Q1 2026.

  • Bank of America held 289,416 shares of Kymera Therapeutics worth $24.1M as of Q1 2026.
  • Bank of America sold 49,583 Kymera Therapeutics shares in Q1 2026, an estimated $3.93M.
  • Kymera Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #2225 holding.
  • Bank of America first reported a position in Kymera Therapeutics in Q3 2020 and has held it in 23 quarters since.
  • Bank of America's Kymera Therapeutics position peaked at $26.4M in Q4 2025.
  • 256 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.